Viatris, Inc. Hits New 52-Week High of $17.68, Up 67.36%

Viatris, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 17.68 on July 21, 2026. This achievement underscores the company's notable performance over the past year, with a remarkable increase of 67.36%, significantly outpacing the S&P 500's growth of 19.09% during the same period. With a market capitalization of USD 15,347 million, Viatris has positioned itself as a key competitor in its industry. The company's financial metrics reveal a dividend yield of 84.69%, indicating a strong return for shareholders despite its current loss-making status, as reflected by the absence of a P/E ratio. Additionally, Viatris maintains a debt-to-equity ratio of 0.89, suggesting a balanced approach to leveraging its financial structure. The stock's previous 52-week low was recorded at USD 8.63, highlighting the significant upward trajectory it has experienced. This milestone reflects the company's ongoing efforts and market dynamics within the pharmaceuticals and biotechnology landscape.